Too Long Didnt Read (TLDR)
Brief summary of Glutathione peptide.
Glutathione, often written GSH, is a three-amino-acid antioxidant made from cysteine, glycine, and glutamate. It is present in nearly every cell and is especially important in liver detoxification and redox balance.
Human research has used oral capsules, liposomal or sublingual formats, intranasal spray, and IV routes. These are not interchangeable, and the evidence behind each route is different.
Oral studies disagree on bioavailability: a six-month RCT found higher body glutathione stores, while older and shorter studies found little or no change after standard oral dosing.
The most repeatable human signal is modest, reversible skin-pigmentation change in oral trials. Liver and Parkinson's disease research is earlier and not definitive.
Injectable and IV glutathione carries the highest risk. FDA and FDA Philippines warnings document sterility, endotoxin, liver, kidney, nervous-system, and severe skin-reaction concerns.
Definition
What glutathione is
Glutathione is the body's most abundant built-in antioxidant. It is a small protein-like molecule called a tripeptide, built from three amino acids: cysteine, glycine, and glutamate. Almost every cell makes it, and the liver makes the most.
The active reduced form is called GSH. After it neutralizes reactive oxygen species, it becomes oxidized glutathione, or GSSG. Cells recycle GSSG back to GSH through glutathione reductase, and researchers often use the GSH-to-GSSG ratio as a marker of oxidative stress.
Because glutathione is endogenous, the research landscape is different from many synthetic research peptides. Oral glutathione is sold as a dietary supplement in the United States, while injectable or IV glutathione is a much higher-risk medical and regulatory category.
Routes
Why route matters
People discuss glutathione as if all forms are the same. They are not. Human studies have used standard oral capsules, liposomal or sublingual forms designed to survive digestion, intranasal spray studied mostly in Parkinson's disease, and IV infusions used in clinics.
Standard oral glutathione is convenient, but bioavailability is debated because intestinal enzymes can break it down. Liposomal and sublingual products try to solve that problem, though many supporting studies are small or formulation-specific. Intranasal glutathione is a separate research route, mostly studied for Parkinson's disease. IV glutathione bypasses the gut entirely but carries the highest safety and sterility risk.
This guide treats route as the central question because benefit claims, study amounts, adverse events, and regulatory concerns change sharply depending on how glutathione is delivered.
- Oral capsules: most common, but absorption is debated.
- Liposomal or sublingual: designed to improve delivery, with small-study support.
- Intranasal: studied mainly in Parkinson's disease research.
- IV or injectable: highest risk and not FDA-approved for cosmetic use.
Mechanism
How glutathione works
In plain English, glutathione is a cellular cleanup molecule. It donates an electron from its cysteine sulfur group to neutralize reactive oxygen species before they damage proteins, membranes, or DNA. The body then recycles spent glutathione back into its active form.
Glutathione also helps the liver process some toxins through conjugation pathways, which is why cysteine supply matters. In acetaminophen overdose, the liver burns through glutathione while processing the drug. The hospital antidote, N-acetylcysteine, works by supplying cysteine so the liver can rebuild glutathione. That is established pharmacology, but it does not mean glutathione supplements are proven treatments for liver disease.
For skin pigmentation, glutathione appears to inhibit tyrosinase and shift pigment production toward lighter pheomelanin rather than darker eumelanin. That mechanism explains the skin-lightening research and also explains why regulators worry about cosmetic misuse and loss of natural UV protection.
Evidence
What the research shows
The oral bioavailability question remains unresolved. Richie and colleagues reported in a 2015 randomized trial that 250 mg/day and 1,000 mg/day oral glutathione for six months increased glutathione stores in blood and other compartments. Allen and Bradley, however, found no change in systemic oxidative-stress biomarkers after 500 mg twice daily for four weeks, and a 1992 single-dose study found no rise after 3 grams in seven participants.
The most consistent human signal is skin pigmentation. Randomized trials using 250-500 mg/day oral glutathione or related formats reported modest melanin-index reductions over weeks, and a 2025 systematic review found this signal across several small studies. The effect appears reversible after stopping and should be understood as cosmetic research, not broad health proof.
Other areas are less settled. A 2017 open-label NAFLD pilot reported improved ALT after 300 mg/day oral glutathione for four months, but the trial was small and uncontrolled. Intranasal glutathione looked safe and tolerable in Parkinson's disease trials, but the Phase IIb study did not clearly beat placebo. Overall, the evidence supports specific route-limited signals, not sweeping claims.
Context
How glutathione compares
Glutathione is most often compared with NAC, liposomal antioxidant formulas, NAD+, and skin-focused peptides such as GHK-Cu. These categories overlap in marketing, but they are not interchangeable.
NAC is not glutathione. It is a precursor that supplies cysteine, the rate-limiting building block your body needs to make glutathione. NAC has stronger drug-level evidence in acetaminophen overdose because it is used clinically for that purpose. Direct oral glutathione has dedicated skin and bioavailability studies but a less settled absorption story.
NAD+ research centers on cellular energy and redox biology, while GHK-Cu is a copper peptide studied for skin remodeling, wound healing, and tissue signaling. Glutathione is better understood as an antioxidant and detoxification molecule than as a tissue-repair peptide.
Boundaries
Safety and regulatory status
Oral glutathione is generally well tolerated in trials, with mild effects such as bloating, loose stools, or cramping reported in some users. That does not mean every product is equivalent. Supplement quality, dose accuracy, and route-specific formulation all matter.
Injectable and IV glutathione is a separate risk category. In 2019, the U.S. FDA warned about compounded sterile injectable glutathione after seven patients had adverse reactions linked to endotoxin contamination. FDA Philippines also warned against IV glutathione for skin lightening, citing risks that include liver, kidney, and nervous-system toxicity, Stevens-Johnson Syndrome, and infection risk from unsafe injection practices.
As of May 2026, oral glutathione can be sold as a dietary supplement in the United States, but no injectable glutathione product is FDA-approved for skin lightening or general wellness. Any route involving injection should be treated as a clinician-supervised medical decision, not a home protocol.
Next
What to review next
For the evidence trail, start with the Richie 2015 oral RCT, the Allen 2011 RCT, the 2025 skin-lightening systematic review, Mischley's intranasal Parkinson's disease studies, and the FDA compounding alert. Those sources show both the promise and the limits.
Within Peptide Advisors, compare glutathione with GHK-Cu for skin and tissue context, KPV for inflammation context, and the GLOW stack for skin-focused peptide-blend context. Peptide Advisors does not publish dosing protocols; for protocol-focused research, review Peptide Dosing Protocols.
Sourcing
Glutathione
Ion Peptide glutathione supplier option for research review. Confirm format, concentration, testing, and current availability on the supplier page.
Buy GlutathioneFAQ
Glutathione FAQs
Short answers for the reusable peptide detail template.
What is glutathione?
Glutathione is an endogenous antioxidant tripeptide made from cysteine, glycine, and glutamate. It helps cells manage oxidative stress, supports liver detoxification pathways, and is recycled between reduced GSH and oxidized GSSG forms.
Is glutathione a peptide?
Yes. Glutathione is a tripeptide, meaning it contains three amino acids. It is much smaller than many research peptides and is naturally produced by the body.
Does oral glutathione actually work?
The evidence is mixed. A 2015 six-month RCT found that oral glutathione increased body stores, while a 2011 trial and an older single-dose study found little or no change. Route, formulation, study length, and biomarkers all matter.
Does glutathione lighten skin?
Several small oral trials reported modest, reversible reductions in melanin index, and a 2025 systematic review found a repeatable signal. This is a cosmetic research finding, not a general health benefit, and regulators have warned against IV glutathione for skin lightening.
Is injectable glutathione FDA-approved?
No injectable glutathione product is FDA-approved in the United States for skin lightening or general wellness. The FDA has warned about compounded injectable glutathione after endotoxin-related adverse events.
How does glutathione compare with NAC?
NAC is a precursor that supplies cysteine so the body can make glutathione. Glutathione is the molecule itself. NAC has established clinical use in acetaminophen overdose, while direct glutathione has a separate and more mixed supplement and cosmetic research record.
Is glutathione safe?
Oral glutathione is generally well tolerated in studies, though mild digestive symptoms can occur. IV and injectable glutathione carries much higher risks, including sterility, contamination, liver, kidney, nervous-system, and severe skin-reaction concerns.
Is this glutathione guide medical advice?
No. This guide is an educational research summary. It is not medical advice, a dosing protocol, or a recommendation to inject glutathione. Talk to a qualified clinician before using glutathione, especially by any injectable route.
References
/ 12Glutathione sources & citations
Primary sourcesPrimary clinical literature and pharmacology references behind this guide.
- 01
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie JP Jr, Nichenametla S, Neidig W, et al. · European Journal of Nutrition · 2015
Six-month oral RCT reporting increased glutathione stores at 250 mg/day and 1,000 mg/day.
- 02
Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers
Allen J, Bradley RD. · Journal of Alternative and Complementary Medicine · 2011
Four-week oral trial finding no significant change in glutathione status or oxidative-stress biomarkers.
- 03
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study
Arjinpathana N, Asawanonda P. · Journal of Dermatological Treatment · 2012
Small oral skin-pigmentation RCT using glutathione as a cosmetic whitening agent.
- 04
An open-label, single-arm trial of a glutathione lozenge as a skin-lightening agent in Filipino women
Handog EB, Datuin MS, Singzon IA. · International Journal of Dermatology · 2016
Open-label lozenge study relevant to sublingual and mucosal delivery discussions.
- 05
Glutathione as a skin-lightening agent and in melasma
Sarkar R, et al. · International Journal of Dermatology · 2025
Systematic review summarizing glutathione skin-lightening evidence and limitations.
- 06
Glutathione and its antiaging and antimelanogenic effects
Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. · Clinical, Cosmetic and Investigational Dermatology · 2017
Clinical study and mechanistic discussion around antimelanogenic effects.
- 07
FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables
U.S. Food and Drug Administration. · FDA Human Drug Compounding · 2019
Primary FDA compounding alert describing adverse events linked to endotoxin contamination.
- 08
FDA Advisory No. 2019-182: Unsafe use of glutathione as skin-lightening agent
Food and Drug Administration Philippines. · FDA Philippines · 2019
Regulatory warning covering IV glutathione risks for skin lightening.
- 09
Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease
Honda Y, Kessoku T, Sumida Y, et al. · BMC Gastroenterology · 2017
Open-label NAFLD pilot study reporting ALT improvement after oral glutathione.
- 10
Phase IIb study of intranasal glutathione in Parkinson's disease
Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. · Journal of Parkinson's Disease · 2017
Intranasal Parkinson's disease study showing tolerability but no clear placebo-beating efficacy.
- 11
A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease
Mischley LK, Leverenz JB, Lau RC, et al. · Movement Disorders · 2015
Early intranasal safety and tolerability study in Parkinson's disease.
- 12
A targeted metabolomic assessment of oral glutathione bioavailability and safety in humans
Schmitt B, et al. · Antioxidants · 2026
Recent human bioavailability and safety study relevant to oral formulation claims.
Medical Disclaimer
This article is provided for educational research purposes only and should not be treated as medical advice. Glutathione is not FDA-approved. Compounded versions should be used only with appropriate physician oversight. Do not begin any peptide protocol without speaking with a licensed healthcare provider, and remember that individual responses can vary significantly.
Written by
Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Garret personally researches, writes, and reviews every guide on Peptide Advisors. Each page is sourced from peer-reviewed clinical trials, systematic reviews, and regulatory filings — with every claim cited and the source hierarchy published openly.
Last reviewed